World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , 

World Journal of Pharmaceutical
and Medical Research

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301

ICV : 78.6



*Dr. Jalaludin, Dr. Zoobia Nisar and Dr. Hafiza Ruqia Arshad


Background: Identifying patients with acute heart failure (HF) at high risk for readmission or death after hospital discharge will enable the optimization of treatment and management. The objective of this study was to develop a risk score for 30-day HF-specific readmission or death in Pakistan. Methods: We analyzed the data from the Pakistan Acute Heart Failure to develop a risk score. The model was derived from a multiple logistic regression analysis using a stepwise variable selection method. We also proposed a point-based risk score to predict the risk of 30-day HF-specific readmission or death by simply summing the scores assigned to each risk variable. Model performance was assessed using an area under the receiver operating characteristic curve (AUC), the Hosmer– Lemeshow goodness-of-fit test, the net reclassification improvement (NRI), and the integrated discrimination improvement (IDI) index to evaluate discrimination, calibration, and reclassification, respectively. Results: Data from 4566 patients aged 40 years were included in the analysis. Among them, 446 (9.8%) had 30-day HF-specific readmission or death. The final model included 12 independent variables (age, New York Heart Association functional class, clinical history of hypertension, HF admission, chronic obstructive pulmonary disease, etiology of cardiomyopathy, systolic blood pressure, left ventricular ejection fraction, serum sodium, brain natriuretic peptide, N-terminal prohormone of brain natriuretic peptide at discharge, and prescription of b-blockers and angiotensinconverting enzyme inhibitors or angiotensin II receptor antagonists at discharge). The point risk score showed moderate discrimination (AUC of 0.710; 95% confidence interval, 0.685–0.735) and good calibration (x2 = 8.540, p = 0.3826).

[Full Text Article]

Powered By WJPMR | All Right Reserved